Developments in the Screening and Prognostication of Melanoma
This peer-to-peer discussion reviews the current strategies for managing patients with melanoma, including screening and prognosis for high-risk patients and how to choose the best therapies to avoid toxicities and treatment resistance.
In this peer-to-peer discussion, Ahmad A. Tarhini, MD, PhD, of the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, and Sancy Leachman, MD, PhD, of the Oregon Health & Science University (OHSU) Knight Cancer Institute in Portland, review the current strategies for managing patients with melanoma, including screening and prognosis for high-risk patients and how to choose the best therapies to avoid toxicities and treatment resistance.
Tarhini and Leachman spoke at an education session on this topic at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Tebentafusp Continues to Demonstrate Benefit in Metastatic Uveal Melanoma
January 4th 2024Results from a long-term analysis of the phase 3 IMCgp100-202 trial indicate that tebentafusp results in better disease control and long-lasting responses in those with HLA-A*02:01–positive, previously untreated metastatic uveal melanoma.
